European Commission logo
English English
CORDIS - EU research results

ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Project description

A needle-free shot of adrenaline

Anaphylactic shock is an extreme allergic reaction that needs to be treated immediately with a shot of epinephrine (adrenaline) to reverse the symptoms. Many people at risk of anaphylaxis carry an autoinjector – a combined syringe and concealed needle that injects a single dose of medication. This needle-based drug delivery device may soon be replaced by a needle-free alternative. Crossject’s ZENEO device permits needle-free injection of the drug in emergency situations. Under the EU-funded ZENEO project, the company plans to launch ZENEO® Adrenaline on the market by the end of 2021. It estimates a turnover of EUR 136 million and a profit of EUR 124 million by the fifth year of commercialisation.


Anaphylactic shock is a serious, life-threatening allergic reaction in which the airways suddenly close; if not properly treated it causes death in 20 minutes. Seventeen million Europeans suffer from food allergies, 3.5 million which are children or young adults. Across Europe, food allergy is the leading cause of anaphylaxis in children aged 0-14 years and there is a huge increase in hospitalizations for allergic reactions in children in the last 10 years. Anaphylaxis sends someone to the emergency room every 3 minutes. The only way to counteract an anaphylactic shock is to inject adrenaline to guarantee enough oxygen to the heart. The adrenaline market is estimated to create revenues of €1.2 billion worldwide, and there is only one big player that produce prefilled syringes.
Crossject already has the know-how to produce pre-filled needle free autoinjectors, our ZENEO® line. We already have 4 ZENEO® products so we are the right company to enter the adrenaline market with a cutting-edge solution.
ZENEO® Adrenaline is an innovative, needle-free, easy-to-use auto-injector suitable for emergency situations, that enables patients and relatives to administer adrenaline. It performs a quick injection (1/10 of a second) avoiding the needle-related discomfort and the risk of contamination, moreover it guarantees intramuscular injection. The end-users of our product are people that are having an anaphylactic shock. People with food allergies are those that will need our device the most as they are more prone to anaphylaxis, however an anaphylactic shock can happen to anyone.
We plan to launch ZENEO® Adrenaline on the market in Q4 2021. We will a turnover of €136M and a profit of €124M by the fifth year of commercialization. We expect to achieve the payback between the second and the third year of commercialization and to generate ROI of 3.36 by the fifth year of commercialization. Moreover, we estimate to create a total of 28 new jobs during these 5 years.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
21000 DIJON

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Bourgogne-Franche-Comté Bourgogne Côte-d’Or
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00